GSK
GSK to cull Australian tablet packaging plant
May 23, 2013Manufacturing and Production Australia, GSK
A GlaxoSmithKline tablet packaging facility in Australia will be closed with the loss of 120 jobs, around a third of …
GSK gets $200m from White House
May 23, 2013Research and Development, Sales and Marketing AMR, BARDA, GSK, HHS, white house
GlaxoSmithKline is to be given up to $200 million by the US government to develop new antibiotics as worries grow …
Funding boost for GSK open lab
May 7, 2013Research and Development, Sales and Marketing GSK, Wellcome
GlaxoSmithKline has been given an extra £5 million by the Wellcome Trust to help support its work in Spain on …
FDA seeks manufacturing data for GSK’s trametinib
May 2, 2013Manufacturing and Production FDA, GSK, melanoma
GlaxoSmithKline’s melanoma drug candidate trametinib has been delayed in the US by an FDA request for more information on its …
GSK abandons Parkinson’s drug
May 1, 2013Research and Development, Sales and Marketing GSK, IPX066, Parkinson's
GlaxoSmithKline has terminated its three-year old agreement with Impax Pharmaceuticals to develop investigational Parkinson’s disease drug IPX066. “The decision has …
GSK submits UMEC monotherapy
April 29, 2013Sales and Marketing COPD, EMA, GSK, UMEC
GlaxoSmithKline has put its investigational once-daily medicine umeclidinium bromide (UMEC) up for scrutiny by European regulators for patients with chronic …
GSK faces £2.6 billion fine
April 19, 2013Sales and Marketing GSK, Seroxat, paroxetine
GlaxoSmithKline could be fined £2.6 billion after the Office of Fair Trading (OFT) alleged it paid generics firms to slow …
FDA delays GSK flu vaccine
March 27, 2013Research and Development, Sales and Marketing FDA, GSK, Vaccine
The FDA has cooled on GlaxoSmithKline’s latest vaccine for a bird flu pandemic, Q-Pan H5N1, despite a vote of confidence …
GSK’s Witty: ‘Drugs should be cheaper’
March 15, 2013Manufacturing and Production, Research and Development, Sales and Marketing ABPI, GSK, Witty
Drugs should be cheaper, GlaxoSmithKline boss Sir Andrew Witty said at a conference this week. His comments, reported by Reuters, …
Hospira woes continue as GSK sues over quality failures
March 5, 2013Manufacturing and Production GSK, Hospira
The difficulties besetting generic firm and contract manufacturer Hospira have taken a new turn with the news that one of …
Abbott, GSK cut staff at Irish facilities
February 26, 2013Manufacturing and Production Abbottt, GSK, Ireland
GlaxoSmithKline and Abbott have both announced job cuts at their facilities in Ireland in a blow to the country’s pharmaceutical …
FDA accepts GSK’s Anoro
February 20, 2013Research and Development, Sales and Marketing FDA, GSK, Theravance, anoro
The FDA has accepted a New Drug Application for GlaxoSmithKline and biopharma firm Theravance’s investigational COPD drug UMEC/VI. A decision …
GSK plans greater use of biocatalysis, continuous processing
February 19, 2013Manufacturing and Production GSK, Witty, biocatalysis
GlaxoSmithKline says it is turning to technology to help improve the cost efficiency of its manufacturing operations, including greater use …
ViiV HIV drug boost
February 18, 2013Sales and Marketing Dolutegravir, GSK, HIV, ViiV
ViiV Healthcare has received a boost with the news that the FDA is to give a priority review to its …
‘Challenging’ Europe slows GSK
February 8, 2013Sales and Marketing GSK, austerity, restructuring
‘Challenging’ economic conditions in Europe are among the factors GlaxoSmithKline is blaming for its sluggish performance, with turnover worldwide down …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
